Pulmonary Hypertension

USMLE Step 1 trap: Applies Group 1 PAH-specific therapies to all forms of pulmonary hypertension regardless of WHO group. PAH-specific vasodilator therapies are indicated only for Group 1 PAH; using them in Group 2 (left heart disease) or Group 3 (lung disease) PH can be harmful by worsening ventilation-perfusion mismatch or causing pulmonary edema.

Pulmonary hypertension is a hemodynamic state, not a single disease — and that distinction is exactly what USMLE Step 1 exploits. Students consistently apply PAH-specific vasodilators (endothelin antagonists, PDE-5 inhibitors, prostacyclins) to all forms of pulmonary hypertension, but these drugs are only appropriate for Group 1 PAH — using them in Group 2 (left heart disease) can flood the pulmonary capillary bed and cause fatal pulmonary edema. The WHO classification divides PH into 5 groups based on etiology, and the exam tests whether you know the difference between treating the underlying cause (Groups 2–5) versus hitting the pulmonary vasculature directly (Group 1). Students who memorize PAH drugs without anchoring them to Group 1 specifically will get burned on management questions. The formal definition requires mean pulmonary arterial pressure ≥20 mmHg at rest, confirmed by right heart catheterization — not echocardiography.

The pathology angle is high yield: Group 1 PAH involves plexiform lesions, medial hypertrophy, and intimal proliferation of pulmonary arterioles — changes that explain why vasodilators work here. Downstream consequence is right ventricular pressure overload, leading to RV hypertrophy, dilation, and eventually cor pulmonale (right heart failure from a pulmonary cause). Step 1 loves asking you to connect RV findings on echo or autopsy back to the underlying pulmonary process.

What makes this topic tricky is the diagnostic layering. Echo screens but doesn't diagnose. RHC diagnoses but is invasive. And for Group 4 (CTEPH), the imaging choice flips — V/Q scan outperforms CT-PA for screening because chronic organized thrombi may not show up well on CT. Students who default to 'CT-PA for PE' will miss the CTEPH-specific logic. USMLE Step 1 rewards knowing not just what test to order, but why.

From real student decks

35%have cards covering this topic

22%have mature cards

A gap in most decks — fewer than half of students in our cohort have cards covering this topic.

Common misconceptions

Common mistake

Wrong: PAH-specific therapies (endothelin receptor antagonists, PDE-5 inhibitors, prostacyclins) are appropriate for all WHO groups of pulmonary hypertension.

Right: PAH-specific vasodilator therapies are indicated only for Group 1 PAH; using them in Group 2 (left heart disease) or Group 3 (lung disease) PH can be harmful by worsening ventilation-perfusion mismatch or causing pulmonary edema.

PAH-specific vasodilators target pulmonary arteriolar tone, which is the primary pathology in Group 1. In Group 2 PH (caused by left heart disease like mitral stenosis or HFpEF), the elevated pulmonary pressures are a back-pressure phenomenon — vasodilating the pulmonary vasculature can flood the pulmonary capillary bed and worsen pulmonary edema. In Group 3 PH, pulmonary vasoconstriction is a protective hypoxic response; blunting it worsens V/Q mismatch and oxygenation. The correct approach for Groups 2–5 is always to treat the underlying cause first.

Common mistake

Wrong: Echocardiography is sufficient to definitively diagnose pulmonary arterial hypertension.

Right: Echocardiography is used for screening and estimates RVSP, but right heart catheterization (RHC) is the gold standard for definitive diagnosis of PAH, measuring mean PAP ≥20 mmHg with PCWP ≤15 mmHg.

Echo is useful and non-invasive — it estimates right ventricular systolic pressure (RVSP) via tricuspid regurgitation jet velocity and can flag patients who need further workup. But 'estimated RVSP elevated on echo' is not a diagnosis of PAH. Right heart catheterization directly measures mean pulmonary arterial pressure and pulmonary capillary wedge pressure (PCWP), which is critical: PAH requires mean PAP ≥20 mmHg AND PCWP ≤15 mmHg (to exclude a left heart cause). You cannot get PCWP from echo, so RHC is irreplaceable for definitive diagnosis.

Common mistake

Gap: Misses V/Q scan as the preferred screening modality for CTEPH over CT pulmonary angiography

V/Q scan is the preferred screening test for chronic thromboembolic pulmonary hypertension (CTEPH, Group 4) because CT-PA may miss chronic organized thrombi; a normal V/Q scan effectively excludes CTEPH.

CT pulmonary angiography is the go-to for acute PE, but CTEPH involves chronic, organized, partially recanalized thrombi that may be isoattenuating to the vessel wall on CT — they can look like normal vessel or subtle filling defects that are easy to miss. V/Q scan detects perfusion defects even when the vessel lumen appears patent on CT, making it more sensitive for CTEPH screening. A normal V/Q scan has high negative predictive value and effectively rules out CTEPH, which is why guidelines recommend it as the first imaging step when CTEPH is suspected.

Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →

Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

Know the definition of pulmonary hypertension (mean PAP ≥20 mmHg) and be able to classify a clinical scenario into the correct WHO group (Group 1 = PAH, Group 2 = left heart disease, Group 3 = lung disease/hypoxia, Group 4 = CTEPH, Group 5 = miscellaneous).
Understand the vascular pathology of PAH — plexiform lesions, medial hypertrophy, intimal proliferation — and trace how sustained RV pressure overload leads to cor pulmonale, including RV hypertrophy and eventual right-sided heart failure.
Distinguish the role of echocardiography (screening tool that estimates RVSP) from right heart catheterization (gold standard for definitive diagnosis, measuring mean PAP and PCWP), and know why V/Q scan is preferred over CT-PA when screening for CTEPH.
Identify which PAH-specific drug classes (endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin analogs) apply to Group 1 only, and recognize that applying them to Group 2 or Group 3 PH is not just unhelpful but potentially dangerous.

Can you avoid these mistakes?

A 45-year-old woman with limited systemic sclerosis is found to have an estimated RVSP of 52 mmHg on echocardiography. What is the next best step to confirm the diagnosis, and what two hemodynamic values must you obtain?

A patient with severe COPD and cor pulmonale is started on sildenafil by a well-meaning intern. Why is this potentially harmful, and which WHO group does this patient belong to?

A 60-year-old man with a history of unprovoked DVT 2 years ago now presents with progressive dyspnea. CT-PA shows no acute PE. Should CTEPH be ruled out? What is the preferred next imaging test and why?

On autopsy of a patient who died from long-standing PAH, the pathologist describes 'plexiform lesions' in the pulmonary arterioles. What is the cellular basis of this finding, and what right heart change would you expect to see grossly?

Pulmonary Hypertension

Common misconceptions

What the exam tests

Can you avoid these mistakes?

Related topics